The company plans to use the funding to accelerate growth and increase production capacity at the company’s New York City-based biotechnology manufacturing facility, according to an Oct. 27 Cresilon news release.
Cresilon began with making hemostatic gel for animals and now has plans to expand into the human health market. The funding round was led by Paulson Investment Co.
